دورية أكاديمية
أعرض في EDS

Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.
المؤلفون: Aljefri YE; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia., Ghaddaf AA; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia., Alkhunani TA; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia., Alkhamisi TA; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia., Alahmadi RA; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia., Alamri AM; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.; Department of Dermatology, King Abdulaziz Medical City, Jeddah, Saudi Arabia., Alraddadi AA; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.; Department of Dermatology, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
المصدر: Dermatologic therapy [Dermatol Ther] 2022 Jul; Vol. 35 (7), pp. e15544. Date of Electronic Publication: 2022 May 13.
نوع المنشور: Journal Article; Meta-Analysis; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-8019 (Electronic) Linking ISSN: 13960296 NLM ISO Abbreviation: Dermatol Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: July/Aug. 2008- : Hoboken, NJ : Wiley-Blackwell
Original Publication: Copenhagen : Munksgaard, c1996-
مواضيع طبية MeSH: Phosphodiesterase 4 Inhibitors*/adverse effects , Psoriasis*/chemically induced , Psoriasis*/diagnosis , Psoriasis*/drug therapy, Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Chronic Disease ; Humans ; Severity of Illness Index ; Thalidomide/adverse effects ; Thalidomide/analogs & derivatives ; Treatment Outcome
مستخلص: Psoriasis is a chronic, inflammatory, immune-mediated disease of the skin and joints. Plaque psoriasis is the most common clinical phenotype of psoriasis. Apremilast is an oral phosphodiesterase type 4 inhibitor recently approved by the US Food and Drug Administration (FDA) for the management of plaque psoriasis. The aim of this systematic review was to assess the efficacy and safety of apremilast monotherapy for the treatment of moderate-to-severe plaque psoriasis. This systematic review included randomized controlled trials (RCTs) comparing apremilast 20 mg twice daily (BID) and 30 mg BID with placebo for its efficacy on plaque psoriasis. We searched the Medline, Embase, and CENTRAL databases. We sought to evaluate the following outcomes: psoriasis area and severity index score (PASI)-50, PASI-75, PASI-90, static Physician Global Assessment (sPGA), and adverse events. The risk ratio (RR) was used to represent dichotomous outcomes and adverse events, and the data were pooled using the inverse variance weighting method. Eight RCTs that enrolled 2635 participants were deemed eligible. Apremilast 30 mg BID and 20 mg BID were significantly more efficacious than placebo in achieving PASI-75 over 16 weeks (RR = 4.60, 95% CI 3.29-6.41, and RR = 3.15, 95% CI 1.96-5.07, respectively). Apremilast 30 mg BID showed a significantly higher rate of adverse events than the placebo (RR = 1.24, 95% CI 1.16-1.33), whereas apremilast 20 mg BID did not exhibit any significant difference (RR = 1.13, 95% CI 0.91-1.42). This meta-analysis demonstrated that apremilast monotherapy is an effective therapeutic option for moderate-to-severe plaque psoriasis with acceptable tolerability and safety profile.
(© 2022 Wiley Periodicals LLC.)
References: Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(2):18-23.
Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study: apremilast in psoriasis. J Eur Acad Dermatol Venereol. 2013;27(3):e376-e383.
Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840-848.
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-285.
Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013;87(9):626-633.
Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III efficacy and safety trial evaluating the effects of apremilast in psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99-105.
Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738-746.
Significant OR in, Psoriasis CMI in Oral OTEZLA® (apremilast) approved by the U.S. food and drug administration for the treatment of patients with moderate to severe plaque psoriasis, August 22, 2021 Q4cdn.com, https://s24.q4cdn.com/483522778/files/doc_news/archive/872240.pdf.
Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507-517.
Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387-1399.
Ohtsuki M, Okubo Y, Komine M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017;44(8):873-884.
Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020;83(1):96-103.
Strober B, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16(8):801-808.
Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37-49.
Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34.
Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Kaaz K, Szepietowski JC, Matusiak Ł. Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis. Acta Derm Venereol. 2019;99(2):175-180.
Komiya E, Tominaga M, Kamata Y, Suga Y, Takamori K. Molecular and cellular mechanisms of itch in psoriasis. Int J Mol Sci. 2020;21(21):8406.
Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871-881.
Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194-199.
Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851-856.
Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(2):69-73.
Cabrera S, Chinniah N, Lock N, Cains GD, Woods J. Inter-observer reliability of the PASI in a clinical setting: inter-observer reliability of the PASI. Australas J Dermatol. 2015;56(2):100-102.
Ighani A, Georgakopoulos JR, Walsh S, Shear NH, Yeung J. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. J Am Acad Dermatol. 2018;78(3):623-626.
Wong TH, Sinclair S, Smith B, Fraser C, Morton CA. Real-world, single-Centre experience of apremilast for the treatment of moderate to severe psoriasis. Clin Exp Dermatol. 2017;42(6):675-676.
Shah BJ, Mistry D, Chaudhary N, Shah S. Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe psoriasis. Indian Dermatol Online J. 2020;11(1):51-57.
Fala L. Otezla (apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8:105.
Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724-1734.
Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality: measures of severity in psoriasis. Br J Dermatol. 1999;141(2):185-191.
Merola JF, Amato DA, See K, et al. Evaluation of sPGA × BSA as an outcome measure and treatment target for clinical practice. J Invest Dermatol. 2018;138(9):1955-1961.
Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2. J Drugs Dermatol. 2017;16(2):147-153.
Chow C, Simpson MJ, Luger TA, Chubb H, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment. J Eur Acad Dermatol Venereol. 2015;29(7):1406-1414.
Callis Duffin K, Bushmakin AG, Cappelleri JC, Mallbris L, Mamolo C. A multi-item physician global assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. BMC Dermatol. 2019;19(1):8.
Gold LS, Papp K, Pariser D, et al. Efficacy and safety of APREMILAST in patients with mild to moderate plaque psoriasis: results of A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022;86(1):77-85.
Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. J Am Acad Dermatol. 2016;75(4):740-746.
Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658-665.
Flytström I, Stenberg B, Svensson Å, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008;158(1):116-121.
Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065-1073.
Kerkhof PCM. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Eur Acad Dermatol Venereol. 2015;29:2002-2010.
Armstrong AW, Robertson AD. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Der. 2013;149(10):1180-1185.
فهرسة مساهمة: Keywords: Psoriasis Area and Severity Index score; apremilast monotherapy; phosphodiesterase 4 inhibitor; plaque psoriasis
المشرفين على المادة: 0 (Anti-Inflammatory Agents, Non-Steroidal)
0 (Phosphodiesterase 4 Inhibitors)
4Z8R6ORS6L (Thalidomide)
UP7QBP99PN (apremilast)
تواريخ الأحداث: Date Created: 20220502 Date Completed: 20220714 Latest Revision: 20221205
رمز التحديث: 20221206
DOI: 10.1111/dth.15544
PMID: 35499185
قاعدة البيانات: MEDLINE
الوصف
تدمد:1529-8019
DOI:10.1111/dth.15544